NASDAQ:MRTXMirati Therapeutics Stock Price, Forecast & News

Mirati Therapeutics' stock was trading at $77.37 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, MRTX shares have increased by 62.6% and is now trading at $125.81.
View which stocks have been most impacted by Coronavirus.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last year. There are currently 3 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Mirati Therapeutics.

Mirati Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Mirati Therapeutics.

Mirati Therapeutics Inc (NASDAQ:MRTX) posted its quarterly earnings results on Thursday, May, 7th. The biotechnology company reported ($2.02) earnings per share for the quarter, missing the consensus estimate of ($1.66) by $0.36. The biotechnology company had revenue of $0.27 million for the quarter, compared to analyst estimates of $0.29 million. Mirati Therapeutics had a negative net margin of 10,983.84% and a negative return on equity of 60.32%. The company's revenue for the quarter was down 78.5% compared to the same quarter last year.
View Mirati Therapeutics' earnings history.

13 brokerages have issued twelve-month target prices for Mirati Therapeutics' stock. Their forecasts range from $83.00 to $163.00. On average, they expect Mirati Therapeutics' share price to reach $123.17 in the next twelve months. This suggests that the stock has a possible downside of 2.1%.
View analysts' price targets for Mirati Therapeutics.

News coverage about MRTX stock has trended very positive this week, InfoTrie reports. The research group scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Mirati Therapeutics earned a news sentiment score of 3.3 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term.
View the latest news about Mirati Therapeutics.

Some companies that are related to Mirati Therapeutics include Genmab A/S (GNMSF), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Shiseido (SSDOY), Beigene (BGNE), Merck KGaA (MKGAF), Alnylam Pharmaceuticals (ALNY), Horizon Therapeutics (HZNP), Catalent (CTLT), Teva Pharmaceutical Industries (TEVA), Sarepta Therapeutics (SRPT), GRIFOLS S A/S (GRFS), GALAPAGOS NV/S (GLPG), Elanco Animal Health (ELAN) and Dr.Reddy's Laboratories (RDY).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirati Therapeutics investors own include NVIDIA (NVDA), Vertex Pharmaceuticals (VRTX), salesforce.com (CRM), Square (SQ), Alibaba Group (BABA), Splunk (SPLK), Advanced Micro Devices (AMD), QUALCOMM (QCOM), AbbVie (ABBV) and Etsy (ETSY).

Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."

Mirati Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Jennison Associates LLC (1.16%), Victory Capital Management Inc. (0.83%), Emerald Advisers LLC (0.43%), Macquarie Group Ltd. (0.42%), Emerald Mutual Fund Advisers Trust (0.39%) and Candriam Luxembourg S.C.A. (0.25%). Company insiders that own Mirati Therapeutics stock include Aaron I Davis, Avoro Capital Advisors Llc, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Christopher C Lemasters, Craig A Johnson, Henry J Fuchs, Isan Chen, Jamie A Donadio, Ltd Braslyn, Michael G Grey and Venbio Select Advisor Llc.
View institutional ownership trends for Mirati Therapeutics.

MRTX stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Victory Capital Management Inc., Emerald Mutual Fund Advisers Trust, Emerald Advisers LLC, Rhenman & Partners Asset Management AB, PNC Financial Services Group Inc., Alps Advisors Inc., and Russell Investments Group Ltd.. Company insiders that have sold Mirati Therapeutics company stock in the last year include Bruce L A Carter, Charles M Baum, Craig A Johnson, Henry J Fuchs, Isan Chen, Ltd Braslyn, and Michael G Grey.
View insider buying and selling activity for Mirati Therapeutics.

MRTX stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Edmond DE Rothschild Holding S.A., Columbus Circle Investors, Mutual of America Capital Management LLC, SG Americas Securities LLC, Swiss National Bank, Candriam Luxembourg S.C.A., and UBS Group AG.
View insider buying and selling activity for Mirati Therapeutics.

Shares of MRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MRTX stock can currently be purchased for approximately $125.81.

Mirati Therapeutics has a market capitalization of $5.60 billion and generates $3.34 million in revenue each year. The biotechnology company earns $-213,260,000.00 in net income (profit) each year or ($5.69) on an earnings per share basis. Mirati Therapeutics employs 63 workers across the globe.

The official website for Mirati Therapeutics is www.mirati.com.

Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-332-3410 or via email at [email protected]